Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Sara E. Oliver(Centers for Disease Control and Prevention), Emily Jane Woo, John R. Su(National Center for Emerging and Zoonotic Infectious Diseases), Danielle Moulia(Centers for Disease Control and Prevention), Kayla E. Hanson(Marshfield Clinic), Nicola P. Klein, Stephen C. Hadler(The Task Force for Global Health), Lauri E. Markowitz(Centers for Disease Control and Prevention), José R. Romero(Boston University), Tom T. Shimabukuro(Centers for Disease Control and Prevention), Kevin C. Ess(Children's Hospital Colorado), Grace M. Lee, H. Keipp Talbot(Marshfield Clinic), Adamma Mba‐Jonas, Meghna Alimchandani, Melinda Wharton(Centers for Disease Control and Prevention), Veronica V. McNally, Narayan Nair(Center for Biologics Evaluation and Research), Naomi K. Tepper(National Center for Chronic Disease Prevention and Health Promotion), Sarah Mbaeyi(National Center for Immunization and Respiratory Diseases), Matthew F. Daley(Kaiser Permanente)
Cited by 215
Related Papers
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k